Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36083778)

  • 1. Artificial intelligence-driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multi-center integration analysis.
    Xu H; Liu Z; Weng S; Dang Q; Ge X; Zhang Y; Ren Y; Xing Z; Chen S; Zhou Y; Ren J; Han X
    Mol Oncol; 2022 Dec; 16(22):4023-4042. PubMed ID: 36083778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-Omics analysis identifies a lncRNA-related prognostic signature to predict bladder cancer recurrence.
    Xu Z; Chen H; Sun J; Mao W; Chen S; Chen M
    Bioengineered; 2021 Dec; 12(2):11108-11125. PubMed ID: 34738881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer.
    Liu Z; Guo C; Dang Q; Wang L; Liu L; Weng S; Xu H; Lu T; Sun Z; Han X
    EBioMedicine; 2022 Jan; 75():103750. PubMed ID: 34922323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer.
    Wang L; Liu Z; Liang R; Wang W; Zhu R; Li J; Xing Z; Weng S; Han X; Sun YL
    Elife; 2022 Oct; 11():. PubMed ID: 36282174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
    Manzano RG; Catalan-Latorre A; Brugarolas A
    BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N6-methylandenosine-related immune genes correlate with prognosis and immune landscapes in gastric cancer.
    Huang Y; Zou Y; Tian Y; Yang Z; Hou Z; Li P; Liu F; Ling J; Wen Y
    Front Oncol; 2022; 12():1009881. PubMed ID: 36523987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an Individualized Prognostic Signature Based on the RWSR Model in Early-Stage Bladder Carcinoma.
    Liu L; Zhong X; Cui H; Zhang H; Wang L; Liu Y
    Biomed Res Int; 2020; 2020():9186546. PubMed ID: 32596394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma.
    Lin P; Wen DY; Chen L; Li X; Li SH; Yan HB; He RQ; Chen G; He Y; Yang H
    Eur Radiol; 2020 Jan; 30(1):547-557. PubMed ID: 31396730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Artificial Intelligence-based Detection of FGFR3 Mutational Status Directly from Routine Histology in Bladder Cancer: A Possible Preselection for Molecular Testing?
    Loeffler CML; Ortiz Bruechle N; Jung M; Seillier L; Rose M; Laleh NG; Knuechel R; Brinker TJ; Trautwein C; Gaisa NT; Kather JN
    Eur Urol Focus; 2022 Mar; 8(2):472-479. PubMed ID: 33895087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling neoantigen-associated genes in bladder cancer: An in-depth analysis employing 101 machine learning algorithms.
    Lv F; Xiong Q; Qi M; Dai C; Zhang X; Cheng S
    Environ Toxicol; 2024 May; 39(5):2528-2544. PubMed ID: 38189174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
    Wang Z; Tu L; Chen M; Tong S
    BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a novel lipid metabolism-related gene prognostic signature and candidate drugs for patients with bladder cancer.
    Zhu K; Xiaoqiang L; Deng W; Wang G; Fu B
    Lipids Health Dis; 2021 Oct; 20(1):146. PubMed ID: 34706720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative analysis of prognostic long non-coding RNAs with copy number variation in bladder cancer.
    Zhong W; Wang D; Yao B; Chen X; Wang Z; Qu H; Ma B; Ye L; Qiu J
    J Zhejiang Univ Sci B; 2021 Aug; 22(8):664-681. PubMed ID: 34414701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular classification reveals the diverse genetic and prognostic features of gastric cancer: A multi-omics consensus ensemble clustering.
    Hu X; Wang Z; Wang Q; Chen K; Han Q; Bai S; Du J; Chen W
    Biomed Pharmacother; 2021 Dec; 144():112222. PubMed ID: 34607103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
    Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
    Front Immunol; 2021; 12():725223. PubMed ID: 34484235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
    Zhao H; Chen Z; Fang Y; Su M; Xu Y; Wang Z; Gyamfi MA; Zhao J
    J Immunol Res; 2022; 2022():1793005. PubMed ID: 35450397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Landscape of Whole-genome Alterations and Pathologic Features in Genitourinary Malignancies: An Analysis of the Cancer Genome Atlas.
    Ball MW; Gorin MA; Drake CG; Hammers HJ; Allaf ME
    Eur Urol Focus; 2017 Dec; 3(6):584-589. PubMed ID: 28753846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.